Natural products for treatment of bone erosive diseases: The effects and mechanisms on inhibiting osteoclastogenesis and bone resorption

International Immunopharmacology

Volumn 36, Issue , 2016, Pages 118-131

  An, Jing ^a   Hao, Dingjun ^a   Zhang, Qian ^a   Chen, Bo ^a   Zhang, Rui ^a   Wang, Yi ^a   Yang, Hao ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Bone resorption; Medical plants; Molecular mechanism; Natural products; Osteoclastogenesis

Indexed keywords

ALKALOID; ANTHRAQUINONE DERIVATIVE; BETA3 INTEGRIN; COLONY STIMULATING FACTOR 1; COUMARIN DERIVATIVE; DITERPENOID; FLAVONOID; GELATINASE B; GLYCOSIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIGNAN; LIMONOID; MITOGEN ACTIVATED PROTEIN KINASE; NATURAL PRODUCT; OSTEOCLAST DIFFERENTIATION FACTOR; PHOSPHATIDYLINOSITOL 3 KINASE; POLYPHENOL; PROTEIN C FOS; PROTEIN KINASE B; SESQUITERPENOID; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR NFATC1; TRITERPENOID; UNCLASSIFIED DRUG;

ARTICLE; BONE EROSION; CALCIUM SIGNALING; CELL FUSION; DISEASE COURSE; DRUG EFFICACY; MACROPHAGE; MARKER GENE; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; PRIORITY JOURNAL; REGENERATIVE MEDICINE; REGULATORY MECHANISM; ANIMAL; ANTAGONISTS AND INHIBITORS; BONE DEVELOPMENT; BONE REGENERATION; DRUG EFFECTS; DRUG THERAPY; HUMAN; PHYSIOLOGY; PHYTOTHERAPY;

ANIMALS; BONE REGENERATION; BONE RESORPTION; HUMANS; OSTEOCLASTS; OSTEOGENESIS; PHYTOTHERAPY; RANK LIGAND;

EID: 84964534093     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2016.04.024     Document Type: Review

References (121)

1. E.F. Eriksen Cellular mechanisms of bone remodeling Rev. Endocr. Metab. Disord. 11 2010 219 227
2. W.J. Boyle, W.S. Simonet, and D.L. Lacey Osteoclast differentiation and activation Nature 423 2003 337 342
3. T. Suda, N. Takahashi, and T.J. Martin Modulation of osteoclast differentiation Endocr. Rev. 13 1991 66 80
4. S. Tanaka, T. Miyazaki, A. Fukuda, T. Akiyama, Y. Kadono, H. Wakeyama, and et al. Molecular mechanism of the life and death of the osteoclast Ann. N. Y. Acad. Sci. 1068 2006 180 186
5. S. Tanaka, K. Nakamura, N. Takahasi, and T. Suda Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system Immunol. Rev. 208 2005 30 49
6. H. Yoshida, S.I. Hayashi, T. Kunisada, M. Ogawa, S. Nishikawa, H. Okamura, and et al. The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene Nature 345 1990 442 444
7. Y.Y. Kong, H. Yoshida, I. Sarosi, H.L. Tan, E. Timms, C. Capparelli, and et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis Nature 397 1999 315 323
8. F.P. Ross M-CSF, c-Fms, and signaling in osteoclasts and their precursors Ann. N. Y. Acad. Sci. 1068 2006 110 116
9. W.W. Jedrzejczak, A. Bartocci, A.W. Ferrante Jr., A. Ahmed-Ansari, K.W. Sell, and et al. Total absence of colony-stimulating factor 1 in the macrophage-deficient osteopetrotic (op/op) mouse Proc. Natl. Acad. Sci. U. S. A. 87 1990 4828 4832
10. H. Takayanagi Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems Nat. Rev. Immunol. 7 2007 292 304
11. H. Hotokezaka, E. Sakai, N. Ohara, Y. Hotokezaka, C. Gonzales, K.I. Matsuo, and et al. Molecular analysis of RANKL-independent cell fusion of osteoclast like cells induced by TNF-alpha, lipopolysaccharide, or peptidoglycan J. Cell. Biochem. 101 2007 122 134
12. S.L. Teitelbaum, and F.P. Ross Genetic regulation of osteoclast development and function Nat. Rev. Genet. 4 2003 638 649
13. S. Takeshita, K. Kaji, and A. Kudo Identification and characterization of the new osteoclast progenitor with macrophage phenotypes being able to differentiate into mature osteoclasts J. Bone Miner. Res. 15 2000 1477 1488
14. M.B. etinkaya, A. Kökçü, F.F. Yanik, T. Başoǧlu, E. Malatyalioglu, and T. Alper Comparison of the effects of transdermal estrogen, oral estrogen, and oral estrogen-progestogen therapy on bone mineral density in postmenopausal women J. Bone Miner. Metab. 20 2002 44 48
15. E. Verron, and J.M. Bouler Is bisphosphonate therapy compromised by the emergence of adverse bone disorders? Drug Discov. Today 19 2014 312 319
16. G.A. Rodan, and T.J. Martin Therapeutic approaches to bone diseases Science 289 2000 1508 1514
17. J.E. Rossouw, G.L. Anderson, R.L. Prentice, A.Z. Lacroix, C. Kooperberg, M.L. Stefanick, and et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial JAMA 288 2002 321 333
18. S.K. Chair, D. Burr, J. Cauley, D.W. Dempster, P.R. Ebeling, D. Felsenberg, and et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research J. Bone Miner. Res. 22 2007 1479 1491
19. 2 +-nuclear factor of activated T-cells cytoplasmic 1 signaling pathways J. Bone Miner. Res. 27 2012 1298 1308
20. A.C. Bharti, Y. Takada, and B.B. Aggarwal Curcumin (diferuloylmethane) inhibits receptor activator of NF-kappa B ligand-induced NF-kappa B activation in osteoclast precursors and suppresses osteoclastogenesis J. Immunol. 172 2004 5940 5947
21. J.H. Lee, H. Jin, H.E. Shim, H.N. Kim, H. Ha, and Z.H. Lee Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-κB signal Mol. Pharmacol. 77 2010 17 25
22. S.Y. Bu, M. Lerner, B.J. Stoecker, E. Boldrin, D.J. Brackett, E.A. Lucas, and et al. Dried plum polyphenols inhibit osteoclastogenesis by downregulating NFATc1 and inflammatory mediators Calcif. Tissue Int. 82 2008 475 488
23. K.S. Lam New aspects of natural products in drug discovery Trends Microbiol. 15 2007 279 289
24. A.L. Harvey Natural products in drug discovery Drug Discov. Today 13 2008 894 901
25. V. Cremasco, C.E. Decker, D. Stumpo, P.J. Blackshear, K.I. Nakayama, K. Nakayama, and et al. Protein kinase C-delta deficiency perturbs bone homeostasis by selective uncoupling of cathepsin K secretion and ruffled border formation in osteoclasts J. Bone Miner. Res. 27 2012 2452 2463
26. S.R. Wilson, C. Peters, P. Saftig, and D. Brömme Cathepsin K activity-dependent regulation of osteoclast actinring formation and bone resorption J. Biol. Chem. 284 2009 2584 2592
27. O. Ishibashi, S. Niwa, K. Kadoyama, and T. Inui MMP-9 antisense oligodeoxynucleotide exerts an inhibitory effect on osteoclastic bone resorption by suppressing cell migration Life Sci. 79 2006 1657 1660
28. J.M. Halleen, S. Räisänen, J.J. Salo, S.V. Reddy, G.D. Roodman, T.A. Hentunen, and et al. Intracellular fragmentation of bone resorption products by reactive oxygen species generated by osteoclastic tartrate-resistant acid phosphatase J. Biol. Chem. 274 1999 22907 22910
29. J.M. Halleen, S.R. Räisänen, S.L. Alatalo, and H.K. Väänänen Potential function for the ROS-generating activity of TRACP J. Bone Miner. Res. 18 2003 1908 1911
30. K. Nemeth, M. Schoppet, N. Al-Fakhri, S. Helas, R. Jessberger, L.C. Hofbauer, and et al. The role of osteoclast-associated receptor in osteoimmunology J. Immunol. 186 2011 113 118
31. K. Matsuo, J.M. Owens, M. Tonko, C. Elliott, T.J. Chambers, and E.F. Wagner Fosl1 is a transcriptional target of c-Fos during osteoclast differentiation Nat. Genet. 24 2000 184 187
32. A.E. Grigoriadis, Z.Q. Wang, M.G. Cecchini, W. Hofstetter, R. Felix, H.A. Fleisch, and et al. c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling Science 266 1994 443 448
33. R. Eferl, A. Hoebertz, A.F. Schilling, M. Rath, F. Karreth, L. Kenner, and et al. The Fos-related antigen Fra-1 is an activator of bone matrix formation EMBO J. 23 2004 2789 2799
34. H. Takayanagi, S. Kim, T. Koga, H. Nishina, M. Isshiki, H. Yoshida, and et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling interminal differentiation of osteoclasts Dev. Cell 3 2002 889 901
35. E.S.M. Ang, P. Zhang, J.H. Steer, J.W.Y. Tan, K. Yip, M.H. Zheng, and et al. Calcium/calmodulin-dependent kinase activity is required for efficient induction of osteoclast differentiation and bone resorption by receptor activator of nuclear factor kappa B ligand (RANKL) J. Cell. Physiol. 212 2007 787 795
36. Z.H. Lee, K. Kwack, K.K. Kim, S.H. Lee, and H.-H. Kim Activation of c-Jun N-terminal kinase and activator protein1 by receptor activator of nuclear factor kappa B Mol. Pharmacol. 58 2000 1536 1545
37. K. Sundaram, R. Nishimura, J. Senn, R.F. Youssef, S.D. London, and S.V. Reddy RANK ligand signaling modulates the matrix metalloproteinase-9 gene expression during osteoclast differentiation Exp. Cell Res. 313 2007 168 178
38. M. Asagiri, K. Sato, T. Usami, S. Ochi, H. Nishina, H. Yoshida, and et al. Autoamplification of NFATc1 expression determines its essential role in bone homeostasis J. Exp. Med. 202 2005 1261 1269
39. P. Soriano, C. Montgomery, R. Geske, and A. Bradley Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice Cell 4 1991 693 702
40. E. Jimi, K. Aoki, H. Saito, F. D'acquisto, M.J. May, I. Nakamura, and et al. Selective inhibition of NF-kappa B blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo Nat. Med. 10 2004 617 624
41. M.G. Ruocco, S. Maeda, J.M. Park, T. Lawrence, L.C. Hsu, Y. Cao, and et al. IκB kinase (IKK) β, but not IKKα, is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss J. Exp. Med. 201 2005 1677 1687
42. 2 Nat. Med. 3 1997 1285 1289
43. P. Monje, J. Hernández-Losa, R.J. Lyons, M.D. Castellone, and J.S. Gutkind Regulation of the transcriptional activity of c-Fos by ERK. A novel role for the prolyl isomerase PIN1 J. Biol. Chem. 280 2005 35081 35084
44. B. Park Triptolide, a diterpene, inhibits osteoclastogenesis, induced by RANKL signaling and human cancer cells Biochimie 105 2014 129 136
45. J. Huang, L. Zhou, Huafeiwu, N. Pavlos, S.M. Chim, Q. Liu, and et al. Triptolide inhibits osteoclast formation, bone resorption, RANKL-mediated NF-κB activation and titanium particle-induced osteolysis in a mouse model Mol. Cell. Endocrinol. 399 2015 346 353
46. Y.J. Wang, X.H. Xu, H. Bingwang, D.L. Wu, X.O. Li, Q.S. Peng, and et al. 17-Hydroxy-jolkinolide a inhibits osteoclast differentiation through suppressing the activation of NF-κB and MAPKs Int. Immunopharmacol. 29 2015 513 520
47. X. Ma, Y. Liu, Y. Zhang, X. Yu, W. Wang, and D. Zhao Jolkinolide B inhibits RANKL-induced osteoclastogenesis by suppressing the activation NF-κB and MAPK signaling pathways Biochem. Biophys. Res. Commun. 445 2014 282 288
48. Z.J. Zhai, H.W. Li, G.W. Liu, X.H. Qu, B. Tian, W. Yan, and et al. Andrographolide suppresses RANKL-induced osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo Br. J. Pharmacol. 171 2014 663 675
49. K. Gan, L. Xu, X. Feng, Q. Zhang, F. Wang, M. Zhang, and et al. Celastrol attenuates bone erosion in collagen-induced arthritis mice and inhibits osteoclast differentiation and function in RANKL-induced RAW264.7 Int. Immunopharmacol. 24 2015 239 246
50. M. Yu, X. Chen, C. Lv, X. Yi, Y. Zhang, M. Xue, and et al. Curcumol suppresses RANKL-induced osteoclast formation by attenuating the JNK signaling pathway Biochem. Biophys. Res. Commun. 447 2014 364 370
51. W.J. Yoon, K.N. Kim, S.J. Heo, S.C. Han, J. Kim, Y.J. Ko, and et al. Sargachromanol G inhibits osteoclastogenesis by suppressing the activation NF-κB and MAPKs in RANKL-induced RAW 264.7 cells Biochem. Biophys. Res. Commun. 434 2013 892 897
52. M. Nepal, H.J. Choi, B.Y. Choi, M.S. Yang, J.I. Chae, L. Li, and et al. Hispidulin attenuates bone resorption and osteoclastogenesis via the RANKL-induced NF-κB and NFATc1 pathways Eur. J. Pharmacol. 715 2013 96 104
53. S.Y. Ko Myricetin suppresses LPS-induced MMP expression in human gingival fibroblasts and inhibits osteoclastogenesis by downregulating NFATc1 in RANKL-induced RAW 264.7 cells Arch. Oral Biol. 57 2012 1623 1632
54. J.C. Jeong, J.W. Lee, C.H. Yoon, H.M. Kim, and C.H. Kim Drynariae Rhizoma promotes osteoblast differentiation and mineralization in MC3T3-E1 cells through regulation of bone morphogenetic protein-2, alkaline phosphatase, type I collagen and collagenase-1 Toxicol. in Vitro 18 2004 829 834
55. S.X. Qiu, C. Dan, L.S. Ding, S. Peng, S.N. Chen, N.R. Farnsworth, and et al. A triterpene glycoside from black cohosh that inhibits osteoclastogenesis by modulating RANKL and TNFα signaling pathways Chem. Biol. 14 2007 860 869
56. B. Cheng, J. Li, J. Du, X. Lv, L. Weng, and C. Ling Ginsenoside Rb1 inhibits osteoclastogenesis by modulating NF-κB and MAPKs pathways Food Chem. Toxicol. 50 2012 1610 1615
57. C. Zhou, W. Liu, W. He, H. Wang, Q. Chen, and H. Song Saikosaponin a inhibits RANKL-induced osteoclastogenesis by suppressing NF-κB and MAPK pathways Int. Immunopharmacol. 25 2015 49 54
58. J. Ha, H.S. Choi, Y. Lee, Z.H. Lee, and H.H. Kim Caffeic acid phenethyl ester inhibits osteoclastogenesis by suppressing NFκB and downregulating NFATc1 and c-Fos Int. Immunopharmacol. 9 2009 774 780
59. Y. Kimira, Y. Taniuchi, S. Nakatani, Y. Sekiguchi, Hyoun Ju Kim, J. Shimizu, and et al. Citrus limonoid nomilin inhibits osteoclastogenesis in vitro by suppression of NFATc1 and MAPK signaling pathways Phytomedicine 22 2015 1120 1124
60. C. Wisutsitthiwong, C. Buranaruk, K. Pudhom, and T. Palaga The plant limonoid 7-oxo-deacetoxygedunin inhibits RANKL-induced osteoclastogenesis by suppressing activation of the NF-κB and MAPK pathways Biochem. Biophys. Res. Commun. 415 2011 361 366
61. Y. He, Q. Zhang, Y. Shen, X. Chen, F. Zhou, and D. Peng Schisantherin A suppresses osteoclast formation and wear particle-induced osteolysis via modulating RANKL signaling pathways Biochem. Biophys. Res. Commun. 449 2014 344 350
62. H.B. Kwak, B.K. Lee, J. Oh, J.T. Yeon, S.W. Choi, H.J. Cho, and et al. Inhibition of osteoclast differentiation and bone resorption by rotenone, through down-regulation of RANKL-induced c-Fos and NFATc1 expression Bone 46 2010 724 731
63. Z. Ouyang, Z. Zhai, H. Li, X. Liu, X. Qu, X. Li, and et al. Hypericin suppresses osteoclast formation and wear particle-induced osteolysis via modulating ERK signalling pathway Biochem. Pharmacol. 90 2014 276 287
64. T. Miyazaki, A. Sanjay, L. Neff, S. Tanaka, W.C. Horne, and R. Baron Src kinase activity is essential for osteoclast function J. Biol. Chem. 279 2004 17660 17666
65. T. Miyazaki, L. Neff, S. Tanaka, W.C. Horne, and R. Baron Regulation of cytochrome c oxidase activity by c-Src in osteoclasts J. Cell Biol. 160 2003 709 718
66. B.R. Wong, D. Besser, N. Kim, J.R. Arron, M. Vologodskaia, H. Hanafusa, and et al. TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src Mol. Cell 4 1999 1041 1049
67. J.B. Moon, J.H. Kim, K. Kim, B.U. Youn, A. Ko, S.Y. Lee, and et al. Akt induces osteoclast differentiation through regulating the GSK3β/NFATc1 signaling cascade J. Immunol. 188 2012 163 169
68. X.D. Peng, P.Z. Xu, M.L. Chen, A. Hahn-Windgassen, J. Skeen, J. Jacobs, and et al. Dwarfism, impaired skin development, skeletal muscle atrophy, delayed bone development, and impeded adipogenesis in mice lacking Akt1 and Akt2 Genes Dev. 17 2003 1352 1365
69. N. Kawamura, F. Kugimiya, Y. Oshima, S. Ohba, T. Ikeda, T. Saito, and et al. Akt1 in osteoblasts and osteoclasts controls bone remodeling PLoS One 2 2007 e1058
70. C.K. Park, Y. Lee, E.J. Chang, M.H. Lee, J.H. Yoon, J.H. Ryu, and et al. Bavachalcone inhibits osteoclast differentiation through suppression of NFATc1 induction by RANKL Biochem. Pharmacol. 75 2008 2175 2182
71. J.Y. Kim, J.Y. Kim, Y.H. Cheon, S.C. Kwak, J.M. Baek, Youn Chul Kime, and et al. 9-Hydroxy-6.7-dimethoxydalbergiquinol inhibits osteoclast differentiation through down-regulation of Akt, c-Fos and NFATc1 Int. Immunopharmacol. 20 2014 213 220
72. H.J. Choi, Y.R. Park, M. Nepal, B.-Y. Choi, N.-P. Cho, S.H. Choi, and et al. Inhibition of osteoclastogenic differentiation by Ikarisoside A in RAW 264.7 cells via JNK and NF-κB signaling pathways Eur. J. Pharmacol. 636 2010 28 35
73. M.H. Kim, S.Y. Ryu, M.A. Bae, J.-S. Choi, Y.K. Min, and S.H. Kim Baicalein inhibits osteoclast differentiation and induces mature osteoclast apoptosis Food Chem. Toxicol. 46 2008 3375 3382
74. K.S. Suh, S.Y. Rhee, Y.S. Kim, Y.S. Lee, and E.M. Choi Xanthohumol modulates the expression of osteoclast-specific genes during osteoclastogenesis in RAW264.7 cells Food Chem. Toxicol. 62 2013 99 106
75. 2 + oscillation PLoS One 9 2014 e88974
76. J.P. Hu, K. Nishishita, E. Sakai, H. Yoshida, Y. Kato, T. Tsukuba, and et al. Berberine inhibits RANKL-induced osteoclast formation and survival through suppressing the NF-κB and Akt pathways Eur. J. Pharmacol. 580 2008 70 79
77. X. Qu, Z. Zhai, X. Liu, H. Li, Z. Ouyang, C. Wu, and et al. Dioscin inhibits osteoclast differentiation and bone resorption though down-regulating the Akt signaling cascades Biochem. Biophys. Res. Commun. 443 2014 658 665
78. H.H. Kim, J.H. Kim, H.B. Kwak, H. Huang, S.H. Han, H. Ha, and et al. Inhibition of osteoclast differentiation and bone resorption by tanshinone IIA isolated from Salvia miltiorrhiza Bunge Biochem. Pharmacol. 67 2004 1647 1656
79. J.M. Baek, J.Y. Kim, Y. Jung, S.H. Moon, M.K. Choi, S.H. Kim, and et al. Mollugin from Rubea cordifolia suppresses receptor activator of nuclear factor-κ B ligand induced osteoclastogenesis and bone resorbing activity in vitro and prevents lipopolysaccharide-induced bone loss in vivo Phytomedicine 22 2015 27 35
80. J. Ma, Y. Ma, X. Liu, S. Chen, C. Liu, A. Qin, and et al. Gambogic acid inhibits osteoclast formation and ovariectomy-induced osteoporosis by suppressing the JNK, p38 and Akt signalling pathways Biochem. J. 469 2015 399 408
81. F.L. Yuan, R.S. Xu, D.L. Jiang, X.L. He, Q. Su, C. Jin, and et al. Leonurine hydrochloride inhibits osteoclastogenesis and prevents osteoporosis associated with estrogen deficiency by inhibiting the NF-κB and PI3K/Akt signaling pathways Bone 75 2015 128 137
82. R. Faccio, and V. Cremasco PLCgamma2: where bone and immune cells find their common ground Ann. N. Y. Acad. Sci. 1192 2010 124 130
83. R.L. Patterson, D.B.V. Rossum, N. Nikolaidis, D.L. Gill, and S.H. Snyder Phospholipase C-gamma: diverse roles in receptor-mediated calcium signaling Trends Biochem. Sci. 30 2005 688 697
84. 2 +-NFATc1 signaling, and suppresses bone loss in mice Bone 60 2014 104 111
85. A.R. Kim, H.S. Kim, J.M. Lee, J.H. Choi, S.N. Kim, D.K. Kim, and et al. Arctigenin suppresses receptor activator of nuclear factor κB ligand(RANKL)-mediated osteoclast differentiation in bone marrow-derived macrophages Eur. J. Pharmacol. 682 2012 29 36
86. N.K. Lee, Y.G. Choi, J.Y. Baik, S.Y. Han, D.W. Jeong, Y.S. Bae, and et al. A crucial role for reactive oxygen species in RANKL-induced osteoclast differentiation Blood 106 2005 852 859
87. K. Bedard, and K.H. Krause The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology Physiol. Rev. 87 2007 245 343
88. T.Y. Hung, T.L. Chen, M.H. Liao, W.P. Ho, D.Z. Liu, W.C. Chuang, and et al. Drynaria fortunei J. Sm. Promotes osteoblast maturation by inducing differentiation-related gene expression and protecting against oxidative stress-induced apoptotic insults J. Ethnopharmacol. 131 2010 70 77
89. X. He, G. Andersson, U. Lindgren, and Y. Li Resveratrol prevents RANKL-induced osteoclast differentiation of murine osteoclast progenitor RAW 264.7 cells through inhibition of ROS production Biochem. Biophys. Res. Commun. 401 2010 356 362
90. K.Y. Han, D. Yang, E.J. Chang, Y. Lee, H. Huang, S.H. Sung, and et al. Inhibition of osteoclast differentiation and bone resorption by sauchinone Biochem. Pharmacol. 74 2007 911 923
91. S.H. Lee, and H.D. Jang Scoparone attenuates RANKL-induced osteoclastic differentiation through controlling reactive oxygen species production and scavenging Exp. Cell Res. 331 2015 267 277
92. S.H. Lee, J.K. Kim, and H.D. Jang Genistein inhibits osteoclastic differentiation of RAW 264.7 cells via regulation of ROS production and scavenging Int. J. Mol. Sci. 15 2014 10605 10621
93. E. Sakai, M. Shimada-Sugawara, Y. Yamaguchi, H. Sakamoto, R. Fumimoto, Y. Fukuma, and et al. Fisetin inhibits osteoclastogenesis through prevention of RANKL induced ROS production by Nrf2-mediated up-regulation of phase II antioxidant enzymes J. Pharmacol. Sci. 121 2013 288 298
94. S. Islam, F. Hassan, G. Tumurkhuu, J. Dagvadorj, N. Koide, Y. Naiki, and et al. Bacterial lipopolysaccharide induces osteoclast formation in RAW 264.7 macrophage cells Biochem. Biophys. Res. Commun. 360 2007 346 351
95. H.J. Chae, R.K. Park, J.S. Kang, H.S. Shin, S.C. Kim, H.T. Chung, and et al. Effect of stem cell factor, interleukin-6, nitric oxide and transforming growth factor-beta on the osteoclast differentiation induced by 1 alpha,25-(OH)2D3 in primary murine bone marrow cultures Pharmacol. Toxicol. 82 1998 223 229
96. T. Taketa, A. Sakai, S. Tanaka, K. Nakai, K. Menuki, H. Yamane, and et al. Selective cyclooxygenase-2 inhibitor prevents reduction of trabecular bone mass in collagen-induced arthritic mice in association with suppression of RANKL/OPG ratio and IL-6 mRNA expression in synovial tissues but not in bone marrow cells J. Bone Miner. Res. 26 2008 143 151
97. M. E, V. C, B. C, O. F, F. A, R. R, and et al. The tumor necrosis factor-{alpha}-blocking agent infliximab inhibits interleukin 1beta (IL-1beta) and IL-6 gene expression in human osteoblastic cells J. Rheumatol. 36 2009 1575 1579
98. J.E. Huh, I.T. Jung, J. Choi, Y.H. Baek, J.D. Lee, D.S. Park, and et al. The natural flavonoid galangin inhibits osteoclastic bone destruction and osteoclastogenesis by suppressing NF-κB in collagen-induced arthritis and bone marrow-derived macrophages Eur. J. Pharmacol. 698 2013 57 66
99. J. Kim, H.K. Lee, T.S. Chang, K.S. Kang, and G.S. Hwang Inhibitory effect of brazilin on osteoclast differentiation and its mechanism of action Int. Immunopharmacol. 29 2015 628 634
100. T.P. Hsieh, S.Y. Sheu, J.S. Sun, and M.H. Chen Icariin inhibits osteoclast differentiation and bone resorption by suppression of MAPKs/NF-κB regulated HIF-1α and PGE2 synthesis Phytomedicine 18 2011 176 185
101. E.S.M. Ang, X.H. Yang, H.H. Chen, Q. Liu, M.H. Zheng, and J.K. Xu Naringin abrogates osteoclastogenesis and bone resorption via the inhibition of RANKL-induced NF-κB and ERK activation FEBS Lett. 585 2011 2755 2762
102. J. Kanehisa, T. Yamanaka, S. Doi, K. Turksen, J.N.M. Heersche, J.E. Aubin, and et al. A band of F-actin containing podosomes is involved in bone resorption by osteoclasts Bone 11 1990 287 293
103. T. Akisaka, H. Yoshida, S. Inoue, and K. Shimizu Organization of cytoskeletal F-actin, G-actin, and gelsolin in the adhesion structures in cultured osteoclast J. Bone Miner. Res. 16 2001 1248 1255
104. S.L. Teitelbaum The osteoclast and its unique cytoskeleton Ann. N. Y. Acad. Sci. 1240 2011 14 17
105. M. Yagi, T. Miyamoto, Y. Sawatani, K. Iwamoto, N. Hosogane, N. Fujita, and et al. DC-STAMP is essential for cell-cell fusion in osteoclasts and foreign body giant cells J. Exp. Med. 202 2005 345 351
106. K. Kim, S.H. Lee, J.H. Kim, Y. Choi, and N. Kim NFATc1 induces osteoclast fusion via upregulation of Atp6v0d2 and the dendritic cell-specific transmembrane protein (DC-STAMP) Mol. Endocrinol. 22 2008 176 185
107. S.N. Kim, M.H. Kim, Y.K. Min, and S.H. Kim Licochalcone A inhibits the formation and bone resorptive activity of osteoclasts Cell Biol. Int. 32 2008 1064 1072
108. T.H. Kim, J.W. Jung, B.G. Ha, J.M. Hong, E.K. Park, H.J. Kim, and et al. The effects of luteolin on osteoclast differentiation, function in vitro and ovariectomy-induced bone loss J. Nutr. Biochem. 22 2011 8 15
109. C.L. Wu, W.G. Wang, B. Tian, X.Q. Liu, X.H. Qu, Z.J. Zhai, and et al. Myricetin prevents titanium particle-induced osteolysis in vivo and inhibits RANKL-induced osteoclastogenesis in vitro Biochem. Pharmacol. 93 2015 59 71
110. S. Yang, X. Li, L. Cheng, H. Wu, C. Zhang, and K. Li Tenuigenin inhibits RANKL-induced osteoclastogenesis by down-regulating NF-κB activation and suppresses bone loss in vivo Biochem. Biophys. Res. Commun. 466 2015 615 621
111. T. Yonezawa, S.I. Hasegawa, M. Asai, T. Ninomiya, T. Sasaki, B.Y. Cha, and et al. Harmine, a β-carboline alkaloid, inhibits osteoclast differentiation and bone resorption in vitro and in vivo Eur. J. Pharmacol. 650 2011 511 518
112. H. Egusa, M. Doi, M. Saeki, S. Fukuyasu, Y. Akashi, Y. Yokota, and et al. The small molecule harmine regulates NFATc1 and Id2 expression in osteoclast progenitor cells Bone 49 2011 264 274
113. H. Li, Z. Zhai, G. Liu, T. Tang, Z. Lin, M. Zheng, and et al. Sanguinarine inhibits osteoclast formation and bone resorption via suppressing RANKL-induced activation of NF-κB and ERK signaling pathways Biochem. Biophys. Res. Commun. 430 2013 951 956
114. J.M. Baek, S.H. Park, Y.H. Cheon, S.J. Ahn, M.S. Lee, J. Oh, and et al. Esculetin attenuates receptor activator of nuclear factor kappa-B ligand-mediated osteoclast differentiation through c-Fos/nuclear factor of activated T-cells c1 signaling pathway Biochem. Biophys. Res. Commun. 461 2015 334 341
115. K.J. Kim, J.T. Yeon, S.W. Choi, S.H. Moon, B.J. Ryu, R. Yu, and et al. Decursin inhibits osteoclastogenesis by downregulating NFATc1 and blocking fusion of pre-osteoclasts Bone 81 2015 208 216
116. H.J. Kim, J.M. Hong, H.J. Yoon, B.M. Kwon, J.Y. Choi, I.K. Lee, and et al. Inhibitory effects of obovatol on osteoclast differentiation and bone resorption Eur. J. Pharmacol. 723 2014 473 480
117. C. Jiang, F. Xiao, X. Gu, Z. Zhai, X. Liu, W. Wang, and et al. Inhibitory effects of ursolic acid on osteoclastogenesis and titanium particle-induced osteolysis are mediated primarily via suppression of NF-kB signaling Biochimie 111 2015 107 118
118. E.K. Park, M.S. Kim, S.H. Lee, K.H. Kim, J.Y. Park, T.H. Kim, and et al. Furosin, an ellagitannin, suppresses RANKL-induced osteoclast differentiation and function through inhibition of MAP kinase activation and actin ring formation Biochem. Biophys. Res. Commun. 325 2004 1472 1480
119. J.W. Lee, Y. Kobayashi, Y. Nakamichi, N. Udagawa, N. Takahashi, N.K. Im, and et al. Alisol-B, a novel phyto-steroid, suppresses the RANKL-induced osteoclast formation and prevents bone loss in mice Biochem. Pharmacol. 80 2010 352 361
120. H.J. Kim, J.M. Hong, J.W. Jung, T.H. Kim, J.A. Kim, Y.H. Kim, and et al. Gymnasterkoreayne F inhibits osteoclast formation by suppressing NFATc1 and DC-STAMP expression Int. Immunopharmacol. 10 2010 1440 1447
121. J.O. Kwon, W.J. Jin, B.J. Kim, H.H. Kim, and Z.H. Lee Myristoleic acid inhibits osteoclast formation and bone resorption by suppressing the RANKL activation of Src and Pyk2 Eur. J. Pharmacol. 768 2015 189 198